Market Overview:
The global seasonal affective disorder market is expected to grow at a CAGR of 5.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing awareness about SAD and its treatment options, rising prevalence of depression, and technological advancements in light therapy devices. The global seasonal affective disorder market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into light therapy, medications, and others. Light therapy is further sub-segmented into conventional light therapy and dawn simulation/light box therapy. Medications are further sub-segmented into antidepressants and antianxiety drugs. Others include cognitive behavior therapies (CBT) and phototherapy treatments such as heliotherapy or heliodonotherapy. On the basis of application, the market is segmented into hospital settings, clinic settings private households setting), other settings (such as prisons or schools),and regions (North America Latin America Europe Asia Pacific Middle East & Africa).
Product Definition:
Seasonal Affective Disorder is a mental health disorder that occurs during the same season every year. The most common symptoms are depression, lack of energy, and changes in sleeping and eating habits. Seasonal Affective Disorder can be treated with light therapy, medication, or counseling.
Light Therapy:
Light therapy is a form of phototherapy used for the treatment of seasonal affective disorder (SAD). It involves exposure to specific wavelengths of light which are believed to be effective in treating symptoms such as depression, fatigue and others.
According to studies, approximately 10% - 15% of people suffering from SAD also suffer from comorbidities along with it. Comorbidity is associated with increased risk for cardiovascular diseases, diabetes and cancer among others.
Medications:
Medications and its usage in seasonal affective disorder (SAD) market is expected to witness lucrative growth over the forecast period owing to increasing prevalence of SAD coupled with rising awareness about the disease. According to National Institute of Mental Health, one out of four people in U.S suffer from some form of season depression each year.
Application Insights:
The seasonally affected individuals find it difficult to adjust with the changing weather and prefer indoor activities. The household application segment led the market in 2017 and is projected to expand further at a steady CAGR over the forecast period. This can be attributed to increasing awareness about GWI among households, especially in countries such as India, China, U.K., Germany and U.S., where most of the seasonal affective disorder cases have been reported recently.
The other segment includes commercial establishments (such as shopping malls) that are open during winters but closed during summers due to low footfall of visitors; these establishments suffer from SAD too but its impact is less compared to that experienced by households or hospitals-based settings owing to isolation from external environment.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position throughout the forecast period owing to increasing awareness about mental health, availability of light therapy, and presence of target population in this region. Moreover, high disposable income and availability of effective treatment methods are anticipated to drive growth during the forecast period.
Asia Pacific is estimated to be fastest-growing regional market from 2018 to 2030 due rising awareness about SAD and easy accessibility for light therapy at home as compared to conventional treatments offered by clinics/hospitals. Furthermore, growing medical tourism industry in emerging countries such as India & China can also be attributed for rapid growth during the forecast period.
Growth Factors:
- Increasing awareness about Seasonal Affective Disorder and its symptoms will drive the growth of the market.
- Rising disposable income of people will lead to an increase in the demand for SAD treatment products and services.
- Growing number of working women population will result in an increase in the demand for SAD treatment products and services.
- Increasing prevalence of depression among people will fuel the growth of Seasonal Affective Disorder market .
Scope Of The Report
Report Attributes
Report Details
Report Title
Seasonal Affective Disorder Market Research Report
By Type
Light Therapy, Medications, Others
By Application
Hospital, Clinic, Household, Other
By Companies
AbbVie Inc. (US), Allergan (Republic of Ireland), Bayer AG (Germany), Bristol-Myers Squibb Company (US), F. Hoffmann-La Roche Ltd. (Switzerland), Henry Schein(US), Pfizer Inc. (US)
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
234
Number of Tables & Figures
164
Customization Available
Yes, the report can be customized as per your need.
Global Seasonal Affective Disorder Market Report Segments:
The global Seasonal Affective Disorder market is segmented on the basis of:
Types
Light Therapy, Medications, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Household, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AbbVie Inc. (US)
- Allergan (Republic of Ireland)
- Bayer AG (Germany)
- Bristol-Myers Squibb Company (US)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Henry Schein(US)
- Pfizer Inc. (US)
Highlights of The Seasonal Affective Disorder Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Light Therapy
- Medications
- Others
- By Application:
- Hospital
- Clinic
- Household
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Seasonal Affective Disorder Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Seasonal affective disorder (SAD) is a type of depression that occurs during certain seasons. It's most common in winter, but it can also occur in summer or fall. SAD is caused by changes in the natural light and dark cycle, which can make people feel depressed.
Some of the major players in the seasonal affective disorder market are AbbVie Inc. (US), Allergan (Republic of Ireland), Bayer AG (Germany), Bristol-Myers Squibb Company (US), F. Hoffmann-La Roche Ltd. (Switzerland), Henry Schein(US), Pfizer Inc. (US).
The seasonal affective disorder market is expected to grow at a compound annual growth rate of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Seasonal Affective Disorder Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Seasonal Affective Disorder Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Seasonal Affective Disorder Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Seasonal Affective Disorder Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Seasonal Affective Disorder Market Size & Forecast, 2018-2028
4.5.1 Seasonal Affective Disorder Market Size and Y-o-Y Growth
4.5.2 Seasonal Affective Disorder Market Absolute $ Opportunity
Chapter 5 Global Seasonal Affective Disorder Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Seasonal Affective Disorder Market Size Forecast by Type
5.2.1 Light Therapy
5.2.2 Medications
5.2.3 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Seasonal Affective Disorder Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Seasonal Affective Disorder Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Household
6.2.4 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Seasonal Affective Disorder Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Seasonal Affective Disorder Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Seasonal Affective Disorder Analysis and Forecast
9.1 Introduction
9.2 North America Seasonal Affective Disorder Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Seasonal Affective Disorder Market Size Forecast by Type
9.6.1 Light Therapy
9.6.2 Medications
9.6.3 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Seasonal Affective Disorder Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Household
9.10.4 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Seasonal Affective Disorder Analysis and Forecast
10.1 Introduction
10.2 Europe Seasonal Affective Disorder Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Seasonal Affective Disorder Market Size Forecast by Type
10.6.1 Light Therapy
10.6.2 Medications
10.6.3 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Seasonal Affective Disorder Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Household
10.10.4 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Seasonal Affective Disorder Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Seasonal Affective Disorder Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Seasonal Affective Disorder Market Size Forecast by Type
11.6.1 Light Therapy
11.6.2 Medications
11.6.3 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Seasonal Affective Disorder Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Household
11.10.4 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Seasonal Affective Disorder Analysis and Forecast
12.1 Introduction
12.2 Latin America Seasonal Affective Disorder Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Seasonal Affective Disorder Market Size Forecast by Type
12.6.1 Light Therapy
12.6.2 Medications
12.6.3 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Seasonal Affective Disorder Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Household
12.10.4 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Seasonal Affective Disorder Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Seasonal Affective Disorder Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Seasonal Affective Disorder Market Size Forecast by Type
13.6.1 Light Therapy
13.6.2 Medications
13.6.3 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Seasonal Affective Disorder Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Household
13.10.4 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Seasonal Affective Disorder Market: Competitive Dashboard
14.2 Global Seasonal Affective Disorder Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 AbbVie Inc. (US)
14.3.2 Allergan (Republic of Ireland)
14.3.3 Bayer AG (Germany)
14.3.4 Bristol-Myers Squibb Company (US)
14.3.5 F. Hoffmann-La Roche Ltd. (Switzerland)
14.3.6 Henry Schein(US)
14.3.7 Pfizer Inc. (US)
